How Is Gilead (NASDAQ:GILD) Stock Positioned Ahead of ESMO This Week?
September 06 2022 - 09:00AM
TipRanks
Biopharmaceutical behemoth Gilead Sciences (GILD) has reported that
new data from a phase 3 study (TROPiCS-02) evaluating Trodelvy
against comparator chemotherapies indicate a progression-free
survival (PFS) in breast cancer patients (irrespective of the
status of their HER2 mutation). Further detailed results are
expected on September 10 at the European Society for Medical
Oncology (ESMO) Congress 2022. Bill Grossman, MD, Ph.D., Senior
Vice president, Therapeutics Area Head, Gilead Oncology commented,
“Trodelvy is already transforming the standard of care in
second-line metastatic triple-negative breast cancer, and we are
excited about its potential in other breast cancers where there is
a significant need for new treatment options.
https://www.tipranks.com/news/article/how-is-gilead-nasdaqgild-stock-positioned-ahead-of-esmo-this-week?utm_source=advfn.com&utm_medium=referral
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Dec 2022 to Jan 2023
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jan 2022 to Jan 2023